LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "severe atopic" as a keyword



Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

Sign Up to like & get
recommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"

DOI: 10.1002/cpdd.1113

Abstract: Tralokinumab is the first biologic therapy for moderate‐to‐severe atopic dermatitis (AD) that specifically neutralizes interleukin‐13 activity, a key driver of AD signs and symptoms. Tralokinumab is a human immunoglobulin G4 monoclonal antibody administered subcutaneously every… read more here.

Keywords: severe atopic; moderate severe; atopic dermatitis; exposure ... See more keywords
Photo from wikipedia

A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis.

Sign Up to like & get
recommendations! Published in 2020 at "Clinical immunology"

DOI: 10.1016/j.clim.2020.108645

Abstract: Hyper-IgE syndrome (HIES) patients may share many features observed in severe atopic dermatitis (SAD), making a diagnostic dilemma for physicians. Determining clinical and laboratory markers that distinguish both disorders could provide early diagnosis and treatment.… read more here.

Keywords: laboratory markers; hyper ige; severe atopic; ige syndrome ... See more keywords

Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Dermatological Treatment"

DOI: 10.1080/09546634.2019.1682503

Abstract: Abstract Background Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective To assess dupilumab effectiveness and safety… read more here.

Keywords: safety; severe atopic; atopic dermatitis; dupilumab ... See more keywords

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Dermatological Treatment"

DOI: 10.1080/09546634.2024.2324833

Abstract: Abstract Background Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe atopic dermatitis (AD): ADvocate1, ADvocate2, and ADhere.… read more here.

Keywords: moderate severe; week; adolescent patients; three randomized ... See more keywords

495 - Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis

Sign Up to like & get
recommendations! Published in 2024 at "British Journal of Dermatology"

DOI: 10.1093/bjd/ljad498.006

Abstract: Lebrikizumab is an interleukin (IL)-13 inhibitor that has completed phase 3 studies. It demonstrated statistical superiority vs. placebo in patients with moderate-to-severe atopic dermatitis (AD) across all primary and key secondary endpoints at week 4… read more here.

Keywords: moderate severe; lebrikizumab; week; severe atopic ... See more keywords

Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results.

Sign Up to like & get
recommendations! Published in 2023 at "Clinical and experimental dermatology"

DOI: 10.1093/ced/llad038

Abstract: BACKGROUND Evidence on tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited. OBJECTIVES To report first experience with tralokinumab treatment in daily practice in AD patients. METHODS In this observational prospective study,… read more here.

Keywords: severe atopic; daily practice; moderate severe; tralokinumab treatment ... See more keywords

The role of access to care in acral lentiginous melanoma survival

Sign Up to like & get
recommendations! Published in 2017 at "British Journal of Dermatology"

DOI: 10.1111/bjd.15713

Abstract: osli S, Kostylina G et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121:122–8. 7 Mendes AM, Costa ACC, Luz S et al. Omalizumab – one year experience in the treatment… read more here.

Keywords: atopic dermatitis; severe atopic; allergy; atopic ... See more keywords

Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment

Sign Up to like & get
recommendations! Published in 2019 at "Clinical and Experimental Dermatology"

DOI: 10.1111/ced.14081

Abstract: Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signalling by binding specifically to the IL-4Rα subunit, shared by both the IL4 and IL-13 receptor complexes (1) recently introduced for the treatment… read more here.

Keywords: severe atopic; treatment; cold urticaria; atopic dermatitis ... See more keywords
Photo by atikahakhtar from unsplash

Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients

Sign Up to like & get
recommendations! Published in 2017 at "Journal of the European Academy of Dermatology and Venereology"

DOI: 10.1111/jdv.14066

Abstract: Cyclosporine A (CSA) is an immunosuppressant agent widely used in severe atopic dermatitis (AD). However, experience in children is limited. read more here.

Keywords: severe atopic; cyclosporine severe; atopic dermatitis; dermatitis children ... See more keywords

Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab

Sign Up to like & get
recommendations! Published in 2024 at "Journal of the European Academy of Dermatology and Venereology"

DOI: 10.1111/jdv.20053

Abstract: Trials and real‐life studies demonstrated clinically meaningful improvements of disease activity in the majority of patients with moderate to severe atopic dermatitis (AD) treated with the anti‐IL‐4RA‐antibody dupilumab. However, misdiagnosis or confounding skin diseases in… read more here.

Keywords: detecting cell; atopic dermatitis; severe atopic; dupilumab ... See more keywords

Association of Severe Atopic Dermatitis with month of birth in Armenian pediatric patients

Sign Up to like & get
recommendations! Published in 2018 at "Pediatric Allergy and Immunology"

DOI: 10.1111/pai.12918

Abstract: Atopic dermatitis (AD) is a chronic relapsing skin disease which affects 15-20% of children worldwide.(1) It is also considered as a major risk factor for developing other atopic diseases including food allergy, asthma and allergic rhinitis later in… read more here.

Keywords: dermatitis month; birth; month birth; atopic dermatitis ... See more keywords